Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00213_DB01030_nanopub.RADkrt2-9T3VSKgFdlq29gfEeR5qY8QFTT8WHh6J735m4#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00213_DB01030 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00213_DB01030 label "DDI between Pantoprazole and Topotecan - The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed. [drugbank_resource:DB00213_DB01030]" assertion.
- drugbank_resource:DB00213_DB01030 identifier "drugbank_resource:DB00213_DB01030" assertion.
- drugbank_resource:DB00213_DB01030 title "DDI between Pantoprazole and Topotecan - The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB01030 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00213_DB01030 assertion.
- drugbank:DB00213 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00213_DB01030 assertion.